信邦制药(002390) - 2022 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2022 was CNY 1,578,346,374.84, an increase of 8.10% compared to CNY 1,460,050,741.08 in Q1 2021[3] - Net profit attributable to shareholders was CNY 73,477,230.21, up 1.80% from CNY 72,181,104.84 in the same period last year[3] - Total operating revenue for the first quarter was CNY 1,578,346,374.84, an increase of 8.1% compared to CNY 1,460,050,741.08 in the same period last year[27] - Net profit for the quarter reached CNY 79,535,695.47, a slight increase from CNY 78,027,582.13 in the previous year, representing a growth of 1.9%[30] - The total comprehensive income for the quarter was CNY 79,535,695.47, compared to CNY 78,027,582.13 in the previous year, showing a slight increase[30] Earnings and Shares - Basic earnings per share decreased by 20.00% to CNY 0.04, down from CNY 0.05 in the previous year[3] - Earnings per share (EPS) for the quarter was CNY 0.04, down from CNY 0.05 in the same period last year[30] - The diluted earnings per share decreased from 0.05 to 0.04 yuan[33] Cash Flow - Net cash flow from operating activities increased by 113.54% to CNY 136,064,884.82, compared to CNY 63,718,809.56 in Q1 2021[3] - Cash inflow from operating activities totaled 1,723,471,374.25 yuan, an increase from 1,572,629,616.06 yuan in the previous period, representing a growth of approximately 9.6%[33] - Cash outflow from operating activities was 1,587,406,489.43 yuan, compared to 1,508,910,806.50 yuan in the previous period, resulting in a net cash flow from operating activities of 136,064,884.82 yuan, up from 63,718,809.56 yuan[33] - The net cash flow from investing activities was CNY -72,216,888.53, a decrease of 32.58% compared to CNY -54,470,786.16 in Q1 2021[7] - The net cash flow from financing activities was CNY -9,290,728.22, a decrease of 121.19% from CNY 43,851,023.26 in the same period last year[7] Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,545,697,701.64, a decrease of 0.86% from CNY 9,628,645,372.98 at the end of the previous year[3] - The company's total liabilities decreased to CNY 2,635,210,410.30 from CNY 2,800,143,777.11, reflecting a reduction of approximately 5.9%[23] - Total equity attributable to shareholders increased to CNY 6,693,239,234.42 from CNY 6,619,762,004.21, marking a growth of about 1.1%[23] - The company's cash and cash equivalents amounted to 639,723,901.72 CNY, an increase from 624,647,651.62 CNY at the beginning of the year[16] - Total current assets decreased to 5,480,123,799.06 CNY from 5,576,368,370.44 CNY[19] Expenses - R&D expenses decreased by 68.49% to CNY 138,626.92, compared to CNY 439,885.17 in the same period last year[7] - Financial expenses decreased by 50.03% to CNY 13,810,161.21, down from CNY 27,637,822.45 in Q1 2021[7] - Total operating costs amounted to CNY 1,490,668,634.89, up 8.6% from CNY 1,372,944,060.87 year-over-year[27] - The company reported a decrease in financial expenses to CNY 13,810,161.21 from CNY 27,637,822.45, a reduction of about 50.0%[27] Shareholder Information - Total number of common shareholders at the end of the reporting period was 92,926[12] - The largest shareholder, Guizhou Jinyu Industrial Investment Partnership, holds 17.76% of shares, totaling 360,000,000 shares[12] - The company has a repurchase account holding 83,376,743 shares, representing 4.11% of total shares[15] Inventory and Receivables - Accounts receivable reached 2,925,042,330.21 CNY, slightly up from 2,891,684,509.29 CNY[16] - The company reported a decrease in inventory to 905,923,378.14 CNY from 935,707,688.64 CNY[19] Audit and Reporting - The company did not conduct an audit for the first quarter report[37]